DOCSLIB.ORG

Supplementary Data Metabolomics Combined with Pattern Recognition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Data Metabolomics Combined with Pattern Recognition Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2017 Supplementary data Metabolomics Combined with Pattern Recognition and Bioinformatics Analysis Methods for the Pharmacodynamic Biomarkers Development on Liver Fibrosis Junwei Fang1#, Liping Wang2#, Yang Wang1, Mingfeng Qiu3*, Yongyu Zhang1,4* 1Center for Traditional Chinese Medicine and Systems Biology, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road,Shanghai 201203,P.R. China 2School of Pharmacy, Fudan University, 826 Zhangheng Road,Shanghai 201203,P.R.China 3School of Pharmacy, Shanhai Jiao Tong University, Shanghai 200240, P.R. China 4School of Traditional Dai Medicine, West Yunnan University of Applied Sciences, Jinghong 600100, P.R. China *To whom correspondence should be address. E-mail: [email protected] Tel.: +86 21 13817553148 Fax: +86 21 51322642. Fig. S1. Retention time deviation profile generated by XCMS. The retention time deviation was < ± 25 s for GC-EI-MS analyses. 100 3 SD 2 SD 50 QC-1 QC-2 QC-3 QC-4 QC-5 ] 1 [ t 0 QC-6 QC-7 QC-8 QC-9 -50 QC-10 2 SD -100 3 SD 1 2 3 4 5 6 7 8 9 10 Num (A) 60 3 SD 40 2 SD QC-6 QC-7 20 QC-8 ] 2 QC-2 QC-9 [ t 0 QC-1 QC-3 QC-4 -20 QC-5 QC-10 -40 2 SD -60 3 SD 1 2 3 4 5 6 7 8 9 10 Num (B) Fig. S2. PCA first and second component for QC samples versus time analyzed. X-axis: run order; Y-axis: standard deviation. All the 10 inserted QC samples are distributed within 2 SD regions. (A) Component 1 versus numbers of the QC samples; (B) Component 2 versus numbers of the QC samples. Table S1 Metabolites identified by searching NIST and Fiehn databases (with minimum match factor > 70%) Rentime Weighted No. HMDB Name (min) Probability 1 2-Methylpropanoic acid 5.3384 88 2 Methylamine 5.3514 86 3 Hydrogen sulfide 6.3016 82 4 N-Methylhydantoin 6.3217 71 5 1,2,4-Trimethylbenzene 6.6884 90 6 Ethylene glycol 6.7602 94 7 Ammonia 7.6413 74 8 6-Hydroxynicotinic acid 7.9977 97 9 Phenol 8.5313 92 10 L-lactic acid 8.629 97 11 2-hydroxybutyric acid 8.7396 87 12 Hexanoic acid 9.0954 71 13 glycolic acid 9.1232 97 14 Pyruvic acid 9.4783 94 15 L-alanine 9.9842 95 16 Hydroxylamine 10.3679 93 17 fumaric acid 10.7721 81 18 oxalic acid 11.0315 96 19 2-furoic acid 11.1874 76 20 Propylene glycol 11.4662 75 21 p-cresol 11.7618 98 22 2-Oxobutanoate 12.0723 88 23 3-Aminoisobutyric acid 13.3459 72 24 L-mimosine 13.5309 88 25 Methylmalonic acid 14.2852 73 26 2-Ethylhydracrylic acid 14.8998 88 27 benzoic acid 15.6611 96 28 (R)-3-Hydroxybutanoate 16.2297 87 29 2-Hydroxyphenethylamine 16.4742 83 30 Octanoic acid 16.4962 95 31 phosphoric acid 17.1094 88 32 nicotinic acid 17.1469 81 33 Malonate 17.2549 95 34 L-Isoleucine 17.5966 83 35 glycerol 17.7021 76 36 L-proline 17.85 92 37 Benzeneacetic acid 17.9581 87 38 glycine 18.2628 97 39 4-Methyl-2-oxopentanoate 18.4186 87 40 2,5-Dihydroxypyridine 18.592 71 41 catechol 18.6399 90 42 succinic acid 18.7984 94 43 5-Hydroxyhexanoic acid 19.3171 71 44 glyceric acid 19.5416 92 45 uracil 19.7378 96 46 Dihydrouracil 19.7408 87 47 Citraconic acid 20.3347 97 48 4-Deoxyerythronic acid 20.5345 71 49 6-Hydroxyhexanoic acid 20.7474 90 50 pipecolic acid 20.8399 97 51 L-serine 20.961 95 52 thymine 21.0999 79 53 L-threonine 22.137 96 54 hydroquinone 22.7779 86 55 Pentanedioic acid 23.1828 85 56 2,4-Dihydroxybutanoic acid 23.4946 85 57 Ethanolamine 23.9927 73 58 3,4-Dihydroxybutanoic acid 24.5231 94 59 Glutaconic acid 24.7282 74 60 (R)-Citramalic acid 26.095 88 61 p-Synephrine 26.1991 85 62 D-malic acid 27.1274 91 63 D-Threitol 27.7658 73 64 adipic acid 27.8881 95 65 D-threitol 28.1041 95 66 L-glutamic acid 28.2395 92 67 L-pyroglutamic acid 28.3047 93 68 cytosine 28.6533 89 69 4-Hydroxy-L-proline 28.6986 76 70 4-guanidinobutyric acid 28.7581 89 71 1,2,3-Trihydroxybenzene 29.0473 70 72 Creatinine 29.6598 91 73 2,3,4-Trihydroxybutanoic acid 29.6747 86 74 L-Cysteine 29.9781 77 75 Mevalonic acid 30.2731 83 76 4-hydroxybenzoic acid 30.4639 84 77 alpha ketoglutaric acid 31.1716 76 78 Heptanedioic acid 31.3488 82 79 Phenylethylamine 31.7576 72 80 hypotaurine 31.7609 93 81 benzene-1,2,4-triol 32.0261 97 82 3-Hydroxymethylglutaric acid 32.2441 96 83 L-Glutamine 33.0994 79 84 4-hydroxyphenylacetic acid 33.748 85 85 D-lyxose 34.2869 96 86 Iso-Valeraldehyde 34.9305 78 87 fructose 35.5219 74 88 3-Hydroxyadipic acid 35.7746 87 89 Octanedioic acid 36.2837 73 90 xylitol 36.6214 97 91 Ribitol 37.1182 78 92 D-Galactose 37.1382 86 93 putrescine 37.3206 95 94 L-fucose 37.5186 83 95 L-arabinopyranose 37.5634 73 96 Valproic acid 37.5859 75 97 orotic acid 37.8253 93 98 cis-aconitic acid 38.1072 93 99 L-Tyrosine 38.1773 78 100 4-hydroxy-3-methoxybenzoic acid 38.3241 85 101 2-Keto-D-gluconic acid 38.4591 91 102 glycerol 1-phosphate 38.5846 86 103 Ribonolactone 38.747 83 104 4-Hydroxymandelate 38.9191 92 105 Azelaic acid 39.4527 77 106 5-hydroxy-L-tryptophan 39.6597 77 107 citric acid 40.1015 94 108 isocitric acid 40.2231 94 109 Cadaverine 40.3072 85 110 3,4-Dihydroxymandelate 40.4212 85 111 homogentisic acid 40.4579 75 112 Indole-2-carboxylic acid 40.5157 75 113 Tartaric acid 40.621 72 114 Dehydroascorbic acid 40.6455 83 115 Myristic acid 40.8564 91 116 hippuric acid 40.9924 97 117 tagatose 41.0679 84 118 adrenaline 41.5688 93 119 gluconic acid lactone 41.5997 88 120 Indole 41.6462 73 121 D-glucose 41.7976 95 122 Myo-Inositol 41.8818 72 123 D-allose 42.3869 92 124 D-mannose 42.4808 95 125 L-Gulonolactone 42.6799 93 126 Mannitol 42.8158 96 127 galacturonic acid 42.918 89 128 Sedoheptulose 42.973 74 129 D-sorbitol 43.0816 91 130 Ascorbic acid 43.2291 75 131 Indole-3-acetate 43.44 81 132 gluconic acid 43.5758 91 133 5-Aminolevulinic acid 43.8236 73 134 Pantothenic acid 44.2091 81 135 Galactonic acid 44.3061 90 136 D-saccharic acid 44.5823 96 137 D-Glucuronic acid 44.9808 91 138 mucic acid 45.3439 98 139 palmitic acid 45.4479 96 140 sebacic acid 45.8127 78 141 N-Acetyl-D-mannosamine 46.0572 90 142 ferulic acid 46.3504 90 143 Uric acid 46.488 97 144 Glucosamine 46.7079 78 145 Elaidic acid 48.7132 90 146 5-Hydroxyindoleacetaldehyde 48.7753 93 147 Oleic acid 48.8529 92 148 stearic acid 49.375 94 149 xanthurenic acid 49.5202 71 150 Pseudouridine 51.0723 75 151 Galactitol 51.9406 78 152 myo-Inositol 1-phosphate 52.4289 74 153 arachidic acid 53.2561 94 154 Sucrose 59.1188 93 155 behenic acid 59.3852 96 156 Alpha-Lactose 61.9974 89 Table S2 Difference metabolites related to CCl4-induced liver fibrosis in rats Fold change No. Metabolite Rentime(min) VIP P value (Model/Normal) 1 2-Methylpropanoic acid 5.34 1.05 0.037 0.52 2 N-Methylhydantoin 6.32 1.51 0.001 0.45 3 1,2,4-Trimethylbenzene 6.69 1.44 0.001 0.35 4 L-lactic acid 8.63 1.42 0.001 0.44 5 Hexanoic acid 9.10 1.57 0.000 0.36 6 glycolic acid 9.12 1.33 0.004 0.60 7 Pyruvic acid 9.48 1.09 0.027 0.59 8 L-alanine 9.98 1.05 0.036 0.71 9 oxalic acid 11.03 1.58 0.000 2.46 10 2-furoic acid 11.19 1.65 0.000 0.22 11 Propylene glycol 11.47 1.13 0.020 0.66 12 3-Aminoisobutyric acid 13.35 1.51 0.000 8.03 13 2-Ethylhydracrylic acid 14.90 1.28 0.007 0.54 14 benzoic acid 15.66 1.03 0.041 0.51 15 (R)-3-Hydroxybutanoate 16.23 1.16 0.023 0.64 16 Octanoic acid 16.50 1.57 0.000 0.21 17 phosphoric acid 17.11 1.07 0.029 1.85 18 Benzeneacetic acid 17.96 1.08 0.028 0.53 19 succinic acid 18.80 1.08 0.028 1.98 20 glyceric acid 19.54 1.61 0.000 0.11 21 4-Deoxyerythronic acid 20.53 1.38 0.003 5.93 22 L-threonine 22.14 1.51 0.000 4.75 23 Pentanedioic acid 22.18 1.20 0.012 2.16 24 (R)-Citramalic acid 26.10 1.38 0.002 2.22 25 p-Synephrine 26.20 1.34 0.003 0.12 26 D-malic acid 27.13 1.44 0.001 5.82 27 L-glutamic acid 28.24 1.16 0.016 2.40 28 L-pyroglutamic acid 28.30 1.34 0.004 2.67 29 cytosine 28.65 1.32 0.004 5.64 30 L-Cysteine 29.98 1.07 0.031 2.09 31 alpha ketoglutaric acid 31.17 1.57 0.000 14.92 32 Phenylethylamine 31.76 1.52 0.001 5.48 33 hypotaurine 31.76 1.52 0.001 5.49 34 3-Hydroxymethylglutaric acid 32.24 1.62 0.000 3.30 35 3-Hydroxyadipic acid 35.77 1.60 0.000 3.29 36 xylitol 36.62 1.41 0.003 1.87 37 L-arabinopyranose 37.56 1.44 0.001 0.46 38 Valproic acid 37.59 1.42 0.001 0.46 39 orotic acid 37.83 1.57 0.000 6.68 40 cis-aconitic acid 38.11 1.43 0.002 6.06 41 4-hydroxy-3-methoxybenzoic acid 38.32 1.36 0.003 3.42 42 2-Keto-D-gluconic acid 38.46 1.41 0.002 0.57 43 Ribonolactone 38.75 1.31 0.005 0.45 44 5-hydroxy-L-tryptophan 39.66 1.33 0.004 0.26 45 citric acid 40.10 1.39 0.002 3.49 46 isocitric acid 40.22 1.30 0.005 26.89 47 homogentisic acid 40.46 1.29 0.006 0.42 48 Dehydroascorbic acid 40.65 1.68 0.000 0.38 49 adrenaline 41.57 1.16 0.016 0.65 50 gluconic acid lactone 41.60 1.25 0.008 0.61 51 Ascorbic acid 43.23 1.65 0.000 0.08 52 gluconic acid 43.58 1.74 0.000 0.20 53 palmitic acid 45.45 1.47 0.001 0.04 54 sebacic acid 45.81 1.07 0.031 3.16 55 ferulic acid 46.35 1.41 0.002 9.10 56 Elaidic acid 48.71 1.35 0.003 0.03 57 5-Hydroxyindoleacetaldehyde 48.78 1.32 0.005 2.60 58 Oleic acid 48.85 1.20 0.013 0.03 59 stearic acid 49.38 1.71 0.000 0.11 60 xanthurenic acid 49.52 1.09 0.035 12.32 61 Galactitol 51.94 1.38 0.004 2.74 62 myo-Inositol 1-phosphate 52.43 1.06 0.047 6.69 63 Sucrose 59.12 1.07 0.036 9.84 Note: VIP means the variable importance in the project; P value was obtained with Student’s t test.
Load more

Recommended publications
  • Cloning, Biochemical Characterization and Inhibition of Alanine Racemase from Streptococcus Iniae
    bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cloning, Biochemical Characterization and Inhibition of Alanine racemase from Streptococcus iniae Murtala Muhammad, Yangyang Li, Siyu Gong, Yanmin Shi, Jiansong Ju, Baohua Zhao*, Dong Liu* College of Life Science, Hebei Normal University, Shijiazhuang 050024, China; *Correspondence: Baohua Zhao and Dong Liu; E-mail: [email protected], [email protected]; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China. Running Title: Inhibitors of alanine racemase Summary statement: Antimicrobial target 1 bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Streptococcus iniae is a pathogenic and zoonotic bacteria that impacted high mortality to many fish species, as well as capable of causing serious disease to humans. Alanine racemase (Alr, EC 5.1.1.1) is a pyridoxal-5′-phosphate (PLP)-containing homodimeric enzyme that catalyzes the racemization of L-alanine and D-alanine. In this study, we purified alanine racemase from the pathogenic strain of S. iniae, determined its biochemical characteristics and inhibitors. The alr gene has an open reading frame (ORF) of 1107 bp, encoding a protein of 369 amino acids, which has a molecular mass of 40 kDa. The optimal enzyme activity occurred at 35°C and a pH of 9.5.
    [Show full text]
  • The Clinical Significance of the Organic Acids Test
    The Clinical Significance of the Organic Acids Test The Organic Acids Test (OAT) provides an accurate metabolic snapshot of what is going on in the body. Besides offering the most complete and accurate evaluation of intestinal yeast and bacteria, it also provides information on important neurotransmitters, nutritional markers, glutathione status, oxalate metabolism, and much more. The test includes 76 urinary metabolite markers that can be very useful for discovering underlying causes of chronic illness. Patients and physicians report that treating yeast and bacterial abnormalities reduces fatigue, increases alertness and energy, improves sleep, normalizes bowel function, and reduces hyperactivity and abdominal pain. The OAT Assists in Evaluating: ■ Krebs Cycle Abnormalities ■ Neurotransmitter Levels ■ Nutritional Deficiencies ■ Antioxidant Deficiencies ■ Yeast and Clostridia Overgrowth ■ Fatty Acid Metabolism ■ Oxalate Levels ■ And More! The OAT Pairs Well with the Following Tests: ■ GPL-TOX: Toxic Non-Metal Chemical Profile ■ IgG Food Allergy + Candida ■ MycoTOX Profile ■ Phospholipase A2 Activity Test Learn how to better integrate the OAT into your practice, along with our other top tests by attending one of our GPL Academy Practitioner Workshops! Visit www.GPLWorkshops.com for workshop dates and locations. The following pages list the 76 metabolite markers of the Organic Acids Test. Included is the name of the metabolic marker, its clinical significance, and usual initial treatment. INTESTINAL MICROBIAL OVERGROWTH Yeast and Fungal Markers Elevated citramalic acid is produced mainly by Saccharomyces species or Propionibacteria Citramalic Acid overgrowth. High-potency, multi-strain probiotics may help rebalance GI flora. A metabolite produced by Aspergillus and possibly other fungal species in the GI tract. 5-Hydroxy-methyl- Prescription or natural antifungals, along with high-potency, multi-strain probiotics, furoic Acid may reduce overgrowth levels.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Orfadin, INN-Nitisinone
    SCIENTIFIC DISCUSSION 1. Introduction 1.1 Problem statement Hereditary tyrosinaemia type 1 (HT-1) is a devastating inherited disease, mainly of childhood. It is characterised by severe liver dysfunction, impaired coagulation, painful neurological crises, renal tubular dysfunction and a considerable risk of hepatocellular carcinoma (Weinberg et al. 1976, Halvorsen 1990, Kvittingen 1991, van Spronsen et al. 1994, Mitchell et al. 1995). The condition is caused by an inborn error in the final step of the tyrosine degradation pathway (Lindblad et al. 1977). The incidence of HT-1 in Europe and North America is about one in 100,000 births, although in certain areas the incidence is considerably higher. In the province of Quebec, Canada, it is about one in 20,000 births (Mitchell et al. 1995). The mode of inheritance is autosomal recessive. The primary enzymatic defect in HT-1 is a reduced activity of fumarylacetoacetate hydrolase (FAH) in the liver, the last enzyme in the tyrosine degradation pathway. As a consequence, fumaylacetoacetate (FAA) and maleylacetoacetate (MAA), upstream of the enzymatic block, accumulate. Both intermediates are highly reactive and unstable and cannot be detected in the serum or urine of affected children. Degradation products of MAA and FAA are succinylacetone (SA) and succinylacetoacetate (SAA) which are (especially SA) toxic, and which are measurable in the serum and urine and are hallmarks of the disease. SA is also an inhibitor of Porphobilinogen synthase (PBG), leading to an accumulation of 5-aminolevulinate (5-ALA) which is thought to be responsible for the neurologic crises resembling the crises of the porphyrias. The accumulation of toxic metabolites starts at birth and the severity of phenotype is reflected in the age of onset of symptoms (Halvorsen 1990, van Spronsen et al.
    [Show full text]
  • Selection and Characterization of Alanine Racemase Inhibitors Against
    Wang et al. BMC Microbiology (2017) 17:122 DOI 10.1186/s12866-017-1010-x RESEARCHARTICLE Open Access Selection and characterization of alanine racemase inhibitors against Aeromonas hydrophila Yaping Wang1, Chao Yang2, Wen Xue1, Ting Zhang1, Xipei Liu1, Jiansong Ju1, Baohua Zhao1* and Dong Liu1* Abstract Background: Combining experimental and computational screening methods has been of keen interest in drug discovery. In the present study, we developed an efficient screening method that has been used to screen 2100 small-molecule compounds for alanine racemase Alr-2 inhibitors. Results: We identified ten novel non-substrate Alr-2 inhibitors, of which patulin, homogentisic acid, and hydroquinone were active against Aeromonas hydrophila. The compounds were found to be capable of inhibiting Alr-2 to different extents with 50% inhibitory concentrations (IC50) ranging from 6.6 to 17.7 μM. These compounds inhibited the growth of A. hydrophila with minimal inhibitory concentrations (MICs) ranging from 20 to 120 μg/ml. These compounds have no activity on horseradish peroxidase and D-amino acid oxidase at a concentration of 50 μM. The MTT assay revealed that homogentisic acid and hydroquinone have minimal cytotoxicity against mammalian cells. The kinetic studies indicated a competitive inhibition of homogentisic acid against Alr-2 with an inhibition constant (Ki) of 51.7 μM, while hydroquinone was a noncompetitive inhibitor with a Ki of 212 μM. Molecular docking studies suggested that homogentisic acid binds to the active site of racemase, while hydroquinone lies near the active center of alanine racemase. Conclusions: Our findings suggested that combining experimental and computational methods could be used for an efficient, large-scale screening of alanine racemase inhibitors against A.
    [Show full text]
  • COMPILATION of AMINO ACIDS, DRUGS, METABOLITES and OTHER COMPOUNDS in MASSTRAK AMINO ACID ANALYSIS SOLUTION Paula Hong, Kendon S
    COMPILATION OF AMINO ACIDS, DRUGS, METABOLITES AND OTHER COMPOUNDS IN MASSTRAK AMINO ACID ANALYSIS SOLUTION Paula Hong, Kendon S. Graham, Alexandre Paccou, T homas E. Wheat and Diane M. Diehl INTRODUCTION LC conditions Physiological amino acid analysis is commonly performed to LC System: Waters ACQUITY UPLC® System with TUV monitor and study a wide variety of metabolic processes. A wide Column: MassTrak AAA Column 2.1 x 150 mm, 1.7 µm variety of drugs, foods, and metabolic intermediates that may Column Temp: 43 ˚C be present in biological fluids can appear as peaks in amino Flow Rate: 400 µL/min. acid analysis, therefore, it is important to be able to identify Mobile Phase A: MassTrak AAA Eluent A Concentrate, unknown compounds.1,2,3 The reproducibility and robustness of diluted 1:10 the MassTrak Amino Acid Analysis Solution make this method well Mobile Phase B: MassTrak AAA Eluent B suited to such a study as well.4 Weak Needle Wash: 5/95 Acetonitrile/Water Strong Needle Wash: 95/5 Acetonitrile/Water Gradient: MassTrak AAA Standard Gradient (as provided in kit) Detection: UV @ 260 nm Injection Volume: 1 µL EXPERIMENTAL Injection Mode: Partial Loop with Needle Overfill (PLNO) Compound sample preparation A library of compounds was assembled. Each compound was derivatized individually and spiked into the MassTrak™ AAA Solution Standard prior to chromatographic analysis. The elution RESULTS AND DISCUSSION position of each tested compound could be related to known amino acids. A wide variety of antibiotics, pharmaceutical compounds and metabolite by-products are found in biological fluids. The reten- 1.
    [Show full text]
  • The Skin in Genetically-Controlled Metabolic Disorders P
    Review Article J Med Genet: first published as 10.1136/jmg.10.2.101 on 1 June 1973. Downloaded from Journal of Medical Genetics (1973). 10, 101. The Skin in Genetically-controlled Metabolic Disorders P. C. H. NEWBOLD Department of Medicine, Cambridge University Medical School, Hills Road, Cambridge CB2 2QL Diseased nature oftentimes breaks forth however, it may lead to difficulty in assessing intelli- In strange eruptions.-Henry IV, part 1, III, i. gence, which is within normal range in 50% of The skin is now commonly accepted as a mirror patients. There is suggestive evidence of a re- of internal disease, but as with other looking-glasses, lationship between subnormal folate levels and low the evidence offered may be selected or ignored. intelligence (Carey et al, 1968), and studies have The epidermis is an interesting structure, especially shown increased turnover of folate coenzymes and rich in tyrosine, phenylalanine, tryptophan, and resulting folate depletion in these patients (Carey et histidine, when compared with the corium (Roth- al, 1968; Butterworth, Krumdieck, and Baugh, man, 1965). Tyrosinaemia and histidinaemia do 1971). There is also a high incidence of an organic not include cutaneous manifestations, but culture of brain syndrome following intracranial vascular skin fibroblasts is a helpful diagnostic tool for study- thromboses (Dunn, Perry, and Dolman, 1966), ing metabolic defects such as citrullinaemia, cysti- copyright. nosis, and maple-syrup urine disease (Scriver, 1969). Most of the conditions now to be described are rare, but if these metabolic diseases were com- mon, there could be no human race as we know it. Homocystinuria http://jmg.bmj.com/ This most informative anomaly was discovered during a study of mentally retarded patients in Ire- land (Carson and Neill, 1962).
    [Show full text]
  • Biochemical Investigations in the Rare Disease Alkaptonuria: Studies on the Metabolome and the Nature of Ochronotic Pigment
    Biochemical Investigations in the Rare Disease Alkaptonuria: Studies on the Metabolome and the Nature of Ochronotic Pigment Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor of Philosophy by Brendan Paul Norman September 2019 ACKNOWLEDGEMENTS It is hard to describe the journey this PhD has taken me on without reverting to well-worn clichés. There has been plenty of challenges along the way, but ultimately I can look back on the past four years with a great sense of pride, both in the work presented here and the skills I have developed. Equally important though are the relationships I have established. I have lots of people to thank for playing a part in this thesis. First, I would like to thank my supervisors, Jim Gallagher, Lakshminarayan Ranganath and Norman Roberts for giving me this fantastic opportunity. Your dedication to research into alkaptonuria (AKU) is inspiring and our discussions together have always been thoughtful and often offered fresh perspective on my work. It has been a pleasure to work under your supervision and your ongoing support and encouragement continues to drive me on. It has truly been a pleasure to be part of the AKU research group. Andrew Davison deserves a special mention - much of the highs and lows of our PhD projects have been experienced together. Learning LC-QTOF-MS was exciting (and continues to be) but equally daunting at the start of our projects (admittedly more so for me as a Psychology graduate turned mass spectrometrist!). I am very proud of what we have achieved together, largely starting from scratch on the instrument, and we are continuing to learn all the time.
    [Show full text]
  • Antioxidants Minerals B-Vitamins
    Patient: SAMPLE PATIENT DOB: Sex: MRN: Results Overview Supplementation Antioxidants for High Need Vitamin A / Carotenoids Vitamin C Vitamin E / Tocopherols α-Lipoic Acid CoQ10 B-Vitamins Thiamin - B1 Riboflavin - B2 Niacin - B3 Pyridoxine - B6 Biotin - B7 Folic Acid - B9 Folic Acid - B9 - Dose = 1,200 mcg Cobalamin - B12 Minerals Magnesium Manganese Molybdenum Zinc © Genova Diagnostics · A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director · CLIA Lic. #34D0655571 · Medicare Lic. #34-8475 GDX-4-214 Patient: SAMPLE PATIENT ID: Page 2 SUGGESTED SUPPLEMENT SCHEDULE Daily Provider Recommended Supplements Patient's Daily Daily Intake (DRI) Recommendations Recommendations Antioxidants Vitamin A / Carotenoids 2,333 IU 5,000 IU Vitamin C 75 mg 250 mg Vitamin E / Tocopherols 22 IU 200 IU α-Lipoic Acid 100 mg CoQ10 60 mg B-Vitamins Thiamin - B1 1.1 mg 25 mg Riboflavin - B2 1.1 mg 25 mg Niacin - B3 14 mg 30 mg Pyridoxine - B6 1.3 mg 10 mg Biotin - B7 30 mcg 100 mcg Folic Acid - B9 400 mcg 1,200 mcg Cobalamin - B12 2.4 mcg 500 mcg Minerals Magnesium 320 mg 600 mg Manganese 1.8 mg 5 mg Molybdenum 45 mcg 75 mcg Zinc 8 mg 20 mg Essential Fatty Acids Omega-3 Oils 500 mg 500 mg Digestive Support Probiotics 25 billion CFU Pancreatic Enzymes 5,000 IU Other Vitamins Vitamin D 600 IU Amino Acid mg/day Amino Acid mg/day Arginine 0 Methionine 0 Asparagine 0 Phenylalanine 0 Cysteine 55 Serine 0 Glutamine 0 Taurine 0 Glycine 0 Threonine 0 Histidine 0 Tryptophan 0 Isoleucine 0 Tyrosine 0 Leucine 0 Valine 0 Lysine 0 Recommendations for age and gender-specific supplementation are set by The Suggested Supplemental Schedule is provided at the request of the comparing levels of nutrient functional need to optimal levels as described in ordering practitioner.
    [Show full text]
  • Analysis of Naturally Occurring Phenolic Compounds in Aromatic Plants by RP-HPLC Coupled to Diode Array Detector (DAD) and GC-MS After Silylation
    Foods 2013, 2, 90-99; doi:10.3390/foods2010090 OPEN ACCESS foods ISSN 2304-8158 www.mdpi.com/journal/foods Article Analysis of Naturally Occurring Phenolic Compounds in Aromatic Plants by RP-HPLC Coupled to Diode Array Detector (DAD) and GC-MS after Silylation Charalampos Proestos 1,†,* and Michael Komaitis 2,† 1 Laboratory of Food Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771, Athens, Greece 2 Laboratory of Food Chemistry and Analysis, Department of Food Science and Technology, Agricultural University of Athens, 11855, Athens, Greece; E-Mail: [email protected] † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +30-210-727-4160 (ext. 160); Fax: +30-210-727-4476. Received: 6 February 2013; in revised form: 4 March 2013 / Accepted: 5 March 2013 / Published: 13 March 2013 Abstract: The following aromatic plants of Greek origin, Origanum dictamnus (dictamus), Eucalyptus globulus (eucalyptus), Origanum vulgare L. (oregano), Mellisa officinalis L. (balm mint) and Sideritis cretica (mountain tea), were examined for the content of phenolic substances. Reversed phase HPLC coupled to diode array detector (DAD) was used for the analysis of the plant extracts. The gas chromatography-mass spectrometry method (GC-MS) was also used for identification of phenolic compounds after silylation. The most abundant phenolic acids were: gallic acid (1.5–2.6 mg/100 g dry sample), ferulic acid (0.34–6.9 mg/100 g dry sample) and caffeic acid (1.0–13.8 mg/100 g dry sample). (+)-Catechin and (−)-epicatechin were the main flavonoids identified in oregano and mountain tea.
    [Show full text]
  • Transfer of Expertise on Rare Metabolic Diseases in Adults
    ALKAPTONURIA Pathophysiology Signs and symptoms Old treatment Prognosis New treatment? Harold W de Valk, endocrinologist Zaira M. Barrientos, researcher University Medical Centre Utrecht The Netherlands Parts of the presentation Background of the disease • Biochemical pathophysiology • Pathology • Genetics Signs and symptoms Complications and prognosis The Dutch survey Current treatment New treatment • How to test effectivity, safety and toxicity in orphan drugs • What about NTBC? Research & Development; outcome analysis Conclusions Background of the disease Deficiency of the enzyme homogentisic acid oxidase Accumulation of homogentisic acid in blood, tissue and urine Rest activity can vary from person to person Biochemical pathway Phenylalanine Tyrosine Tyrosine amino transaminase Phenylalanine hydroxylase 4 Hydroxyphenylpyruvate 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) Homogentisic acid Deficiency in Homogentisate 1,2-dioxygenase Alkaptonuria Maleylacetoacetate Maleylacetoacetate Porphobilinogen isomerase Fumarylacetoacetate Deficiency in Hereditary Fumarylacetoacetase tyrosinaemia I Fumarate + Acetoacetate Tricyclic acid cycle Genetic defect Pathophysiologic pathway Pathogenesis Excess HGA Excess HGA Excess HGA in plasma in urine Polyphenol Polymers Binding to oxidase in tissue sulhydrylgroups BQA Binding to collagen Free radical damage Cartilage damage Joint disease Genetics Autosomal recessive disease Many DNA-mutations Detected hot spots: • a valley in Slovakia • Dominican republic − geographically and socially
    [Show full text]
  • Evaluation of Antioxiodant Drugs for the Treatment of Ochronotic Alkaptonuria in an in Vitro Human Cell Model
    ORIGINAL ARTICLE 84 JournalJournal ofof Cellular Evaluation of Antioxiodant Drugs Physiology for the Treatment of Ochronotic Alkaptonuria in An In Vitro Human Cell Model LAURA TINTI,1 ADRIANO SPREAFICO,1,2** DANIELA BRACONI,3 LIA MILLUCCI,3 GIULIA BERNARDINI,3 FEDERICO CHELLINI,1 GIOVANNI CAVALLO,2 ENRICO SELVI,1,2 MAURO GALEAZZI,2,3 ROBERTO MARCOLONGO,2 JAMES A. GALLAGHER,2,4 2,3 AND ANNALISA SANTUCCI * 1Sezione di Reumatologia, Dipartimento di Medicina Clinica e Scienze Immunologiche, Universita` degli Studi di Siena, Policlinico Le Scotte, Siena, Italy 2Centro Interdipartimentale per lo Studio Biochimico delle Patologie Osteoarticolari, Universita` degli Studi di Siena, Siena, Italy 3Dipartimento di Biologia Molecolare, Universita` degli Studi di Siena, Siena, Italy 4Department of Human Anatomy & Cell Biology, University of Liverpool, Liverpool, UK Alkaptonuria (AKU) is a rare autosomal recessive disease, associated with deficiency of homogentisate 1,2-dioxygenase activity in the liver. This leads to an accumulation of homogentisic acid (HGA) and its oxidized derivatives in polymerized form in connective tissues especially in joints. Currently, AKU lacks an appropriate therapy. Hence, we propose a new treatment for AKU using the antioxidant N- acetylcysteine (NAC) administered in combinations with ascorbic acid (ASC) since it has been proven that NAC counteracts the side- effects of ASC. We established an in vitro cell model using human articular primary chondrocytes challenged with an excess of HGA (0.33 mM). We used this experimental model to undertake pre-clinical testing of potential antioxidative therapies for AKU, evaluating apoptosis, viability, proliferation, and metabolism of chondrocytes exposed to HGA and treated with NAC and ASC administered alone or in combination addition of both.
    [Show full text]